Current status of oral chemotherapy for colorectal cancer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing an alternative to intravenous delivery while at the same time improving the quality of life of patients who require fluorouracil for advanced or adjuvant therapy has provided the stimulus for the development of oral fluoropyrimidine drugs. Five oral fluoropyrimidine drugs have recently entered clinical trials in the United States. These include capecitabine (Xeloda), UFT (uracilandtegafur) or UFT/leucovorin (Orzel), eniluracil (ethynyluracil), S-1, and BOF A-2. At least two of these drugs have demonstrated survival equivalent to the standard intravenous fluorouracil and leucovorin regimens used to treat advanced colorectal cancer. This, together with less severe toxicity and potential increased quality of life, should lead to approval of one or more of these oral agents in the near future. Based on both patient and physician acceptance of oral fluoropyrimidines, other oral drugs from classes other than fluoropyrimidines will likely be developed in the near future.

Original languageEnglish (US)
Pages (from-to)16-20
Number of pages5
JournalOncology
Volume15
Issue number3 SUPPL. 5
StatePublished - 2001
Externally publishedYes

Fingerprint

Fluorouracil
Colorectal Neoplasms
Drug Therapy
Leucovorin
Pharmaceutical Preparations
Quality of Life
varespladib methyl
Clinical Trials
Physicians
Survival
Therapeutics
Capecitabine

ASJC Scopus subject areas

  • Oncology

Cite this

Current status of oral chemotherapy for colorectal cancer. / Diasio, Robert B.

In: Oncology, Vol. 15, No. 3 SUPPL. 5, 2001, p. 16-20.

Research output: Contribution to journalArticle

Diasio, Robert B. / Current status of oral chemotherapy for colorectal cancer. In: Oncology. 2001 ; Vol. 15, No. 3 SUPPL. 5. pp. 16-20.
@article{75e1b46c56464178a7299d7e497951f7,
title = "Current status of oral chemotherapy for colorectal cancer",
abstract = "The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing an alternative to intravenous delivery while at the same time improving the quality of life of patients who require fluorouracil for advanced or adjuvant therapy has provided the stimulus for the development of oral fluoropyrimidine drugs. Five oral fluoropyrimidine drugs have recently entered clinical trials in the United States. These include capecitabine (Xeloda), UFT (uracilandtegafur) or UFT/leucovorin (Orzel), eniluracil (ethynyluracil), S-1, and BOF A-2. At least two of these drugs have demonstrated survival equivalent to the standard intravenous fluorouracil and leucovorin regimens used to treat advanced colorectal cancer. This, together with less severe toxicity and potential increased quality of life, should lead to approval of one or more of these oral agents in the near future. Based on both patient and physician acceptance of oral fluoropyrimidines, other oral drugs from classes other than fluoropyrimidines will likely be developed in the near future.",
author = "Diasio, {Robert B}",
year = "2001",
language = "English (US)",
volume = "15",
pages = "16--20",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3 SUPPL. 5",

}

TY - JOUR

T1 - Current status of oral chemotherapy for colorectal cancer

AU - Diasio, Robert B

PY - 2001

Y1 - 2001

N2 - The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing an alternative to intravenous delivery while at the same time improving the quality of life of patients who require fluorouracil for advanced or adjuvant therapy has provided the stimulus for the development of oral fluoropyrimidine drugs. Five oral fluoropyrimidine drugs have recently entered clinical trials in the United States. These include capecitabine (Xeloda), UFT (uracilandtegafur) or UFT/leucovorin (Orzel), eniluracil (ethynyluracil), S-1, and BOF A-2. At least two of these drugs have demonstrated survival equivalent to the standard intravenous fluorouracil and leucovorin regimens used to treat advanced colorectal cancer. This, together with less severe toxicity and potential increased quality of life, should lead to approval of one or more of these oral agents in the near future. Based on both patient and physician acceptance of oral fluoropyrimidines, other oral drugs from classes other than fluoropyrimidines will likely be developed in the near future.

AB - The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing an alternative to intravenous delivery while at the same time improving the quality of life of patients who require fluorouracil for advanced or adjuvant therapy has provided the stimulus for the development of oral fluoropyrimidine drugs. Five oral fluoropyrimidine drugs have recently entered clinical trials in the United States. These include capecitabine (Xeloda), UFT (uracilandtegafur) or UFT/leucovorin (Orzel), eniluracil (ethynyluracil), S-1, and BOF A-2. At least two of these drugs have demonstrated survival equivalent to the standard intravenous fluorouracil and leucovorin regimens used to treat advanced colorectal cancer. This, together with less severe toxicity and potential increased quality of life, should lead to approval of one or more of these oral agents in the near future. Based on both patient and physician acceptance of oral fluoropyrimidines, other oral drugs from classes other than fluoropyrimidines will likely be developed in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0035289240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035289240&partnerID=8YFLogxK

M3 - Article

C2 - 11301835

AN - SCOPUS:0035289240

VL - 15

SP - 16

EP - 20

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3 SUPPL. 5

ER -